Circulating tumor DNA assessment in patients with diffuse large B-cell lymphoma following CAR T-cell therapy

Metabolic Tumor Volume Metrics in Lymphoma

(2018) Lale Kostakoglu et al.   SEMINARS IN NUCLEAR MEDICINE

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

(2017) Sattva S. Neelapu et al.   NEW ENGLAND JOURNAL OF MEDICINE

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing

(2015) D. M. Kurtz et al.   BLOOD

Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study

(2015) Mark Roschewski et al.   LANCET ONCOLOGY

Immunoglobulin and T Cell Receptor Gene High-Throughput Sequencing Quantifies Minimal Residual Disease in Acute Lymphoblastic Leukemia and Predicts Post-Transplantation Relapse and Survival

(2014) Aaron C. Logan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma

(2014) Myriam Sasanelli et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia

(2013) A C Logan et al.   LEUKEMIA

Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia

(2012) M. Faham et al.   BLOOD

Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement

(2011) Moo-Kon Song et al.   ANNALS OF HEMATOLOGY

High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment

(2011) A. C. Logan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA